The drug received standard U.S. approval in 2023 after showing it slowed cognitive decline in patients with the brain-wasting ...

Japanese pharmaceutical company Eisai Co. and U.S. firm Biogen Inc. said Monday that a jointly developed Alzheimer's drug has ...

Air pollution may be a cause of dementia, Stockholm, Sweden study found that PM2.5 levels in air pollution increased risk of ...

Alzheimer's is a progressive disorder that gradually impairs multiple brain functions over several years - but a new study ...

“The problem with the Alzheimer’s group is they were very co-opted,” said Peter J. Whitehouse, MD, PhD, a professor of ...

Revolutionary nasal spray offers hope by potentially delaying Alzheimer's progression through cutting-edge neurological ...

INTELLIGENCE leads to better decision-making and problem-solving in various aspects of life.  But a new study has identified ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...

Biogen and Eisai’s Alzheimer’s disease (AD) drug Leqembi (lecanemab-irmb) has been approved by the US Food and Drug ...

BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has approved ...

Think your brain is too old to learn new tricks, let alone keep cognitive decline at bay? Think again. Research featured in the journal Cell Stem Cell in 2019 revealed that neurons continue to form in ...

Tokyo: Eisai Co., Ltd. and Biogen Inc. have announced that the U.S. Food and Drug Administration (FDA) has approved the ...